"Teriflunomide" Pronounce,Meaning And Examples

"Teriflunomide" Meaning

Teriflunomide is a disease-modifying anti-rheumatic drug (DMARD) that is used to treat multiple sclerosis (MS) and rheumatoid arthritis. It is believed to work by slowing down the progression of the disease by reducing the number of immune cells (T cells) that attack the central nervous system.

The exact mechanism of action of teriflunomide is not fully understood, but it is thought to targets several pathways involved in the development of immune responses, including:

Inhibiting the replication of T cells
Reducing the activity of adenosine receptors, which are involved in the regulation of immune responses
Modulating the function of certain chemokines, which are signaling proteins that attract immune cells to the site of inflammation.

Teriflunomide has been shown to be effective in reducing the frequency of relapses in patients with MS and slowing down the progression of physical disability. However, it can cause a range of side effects, including nausea, vomiting, diarrhea, fatigue, and liver damage.

"Teriflunomide" Examples

Usage Examples of "Teriflunomide"

Medical Term Definition

Teriflunomide is a medication used to treat multiple sclerosis.

Usage Examples:

1. Medical Prescription: The doctor prescribed teriflunomide to the patient for the treatment of relapsing forms of multiple sclerosis.

2. Side Effects Discussion: Patients taking teriflunomide may experience side effects such as hair loss, nausea, and elevated liver enzymes.

3. New Treatment Option: The recent clinical trial demonstrated that teriflunomide was as effective as interferon beta-1a in reducing the activity of relapsing multiple sclerosis without the transfusion risks.

4. Pharmacological Studies: In in vitro and in vivo studies, teriflunomide has been shown to exhibit immunomodulatory properties that are beneficial in the treatment of autoimmune diseases.

5. Treatment Guidelines: According to clinical guidelines for multiple sclerosis management, teriflunomide can be considered in patients with higher levels of disease activity who did not respond well to other disease-modifying therapies.